Cardiac xenotransplantation (CXTx) remains a promising approach to alleviate the chronic shortage of donor hearts. This review summarizes recent results of heterotopic and orthotopic CXTx, highlights the role of non-Gal antibody in xenograft rejection, and discusses challenges to clinical orthotopic CXTx.
INTRODUCTION
The chronic shortage of donor organs limits the full benefit of organ transplantation as a therapy for end-stage organ failure. This factor has spurred interest in alternative therapies, including mechanical devices, regenerative medical approaches, and xenotransplantation. Left ventricular assist devices, used as a bridge to transplant or as destination therapy, are effective for patients with end-stage heart failure [1] . Changes in device design and patient selection have improved survival, although infections and bleeding complications remain. As destination therapy, mechanical devices may not provide an equal quality of life compared to organ transplantation. Regenerative medicine promises immunologically compatible organs produced from recipient progenitor cells. This approach has had good success for simple tissues [2] , but regenerative medicine for heart transplantation remains at a nascent stage [3] . Genetic modification of the porcine genome has transformed xenotransplantation [4] . Survival of pig-to-primate cardiac xenotransplantation (CXTx) has increased from a few hours to a median of 3 months [5] . If replicated using life-supporting orthotopic transplants, CXTx may warrant clinical testing. This review summarizes recent developments in heterotopic and orthotopic CXTx and highlights the role of non-Gal antibodymediated endothelial cell activation as a primary effector of delayed xenograft rejection (DXR).
ELIMINATION OF THE aGAL ANTIGEN
It has been nearly 10 years since the development of pigs with a targeted mutation in the a-galactosyltransferase gene [6, 7] (GGTA-1; GTKO pigs). This gene encodes the enzymatic function to produce the galactose a1,3, galactose glycan (aGal). Initially, there was concern that residual levels of aGal might persist in GTKO pigs. Residual aGal expression was detected on cultured GTKO porcine fetal fibroblasts isolated after in-vitro selection of GT þ/cells [8] and a second a-galactosyltransferase, encoding the production of the rat isogloboside iGb3, was shown to induce aGal expression in human cells [9] . This suggested that GTKO pigs might still produce aGal glycolipids. This is not the case. Cells from GTKO pigs fail to bind the aGal-specific lectin GSIB-4 or any of a series of anti-Gal monoclonal antibodies ( [10] and GWB personal communication). Comparisons of neutral and acidic glycolipids from Galpositive and GTKO pig organs found no evidence of aGal in GTKO tissues [11] and molecular analysis failed to observe expression of the iGb3 a-galactosyltransferase in GTKO pig cells [12] . Xenotransplantation of GTKO hearts has no effect on preformed anti-Gal antibody and does not stimulate an anti-Gal antibody response [13, 14] . These findings indicate that the GTKO mutation has eliminated the aGal antigen from pig tissues and marginalized any role of anti-Gal antibody in rejection of GTKO donor organs.
HETEROTOPIC GTKO CARDIAC TRANSPLANTS
The initial pig-to-primate GTKO cardiac xenografts observed no hyperacute rejection and obtained a median cardiac xenograft survival of 78 days [13] . Recipients in this study were strongly immunosuppressed and showed hyporesponsive cellular reactivity and no notable induction of non-Gal antibody. Despite effective immune regulation and use of recipients with minimal pretransplant non-Gal antibody, DXR of GTKO hearts showed vascular antibody and complement deposition along with platelet and fibrin-rich microvascular thrombosis. The extent of microvascular thrombosis paralleled increases in antibody and complement deposition, endothelial cell expression of tissue factor and von Willebrand factor, and decreased expression of CD39 [15] . We recently compared the histopathology of GT þ ;CD46 and GTKO;CD55 cardiac xenograft rejection [14] . Despite depletion of anti-Gal antibody for GT þ graft recipients prior to transplant, both donor types show vascular antibody deposition within 30 min of reperfusion and in all subsequent interim biopsies. Complement activation occurred, as evidenced by C3d deposition. Vascular deposition of C5b and C5b-9 were minimal, consistent with the intrinsic regulatory function of CD46 or CD55. Early histopathology showed myocyte vacuolization, generally prior to significant levels of microvascular thrombosis, followed by increasing levels of microvascular thrombosis, ischemic injury, and myocardial coagulative necrosis ( Fig. 1 ). These later histologic features paralleled decreased cardiac contractility and increased levels of serum troponin. Elevated expression of porcine intracellular adhesion molecule 1, vascular cell adhesion molecule 1, and tissue factor, consistent with endothelial cell activation, was observed at explant. This study and others using GT þ donors suggests that when early effects of anti-Gal antibody are blocked, the histopathology of DXR is the same in both GT þ and GTKO cardiac xenografts [16, 17] . Together these studies strongly indicate that rejection of GTKO organs remains primarily an antibody-mediated process resultant to non-Gal antibody-mediated injury or activation of vascular endothelial cells.
NON-GAL ANTIGENS AND CARDIAC XENOGRAFT REJECTION
The natural antibody repertoire consists of germline-encoded polyreactive antibody (IgM) produced in the absence of clear immune challenge [18, 19] . Natural antibody also includes reactivity to aGal and to blood groups A and B glycans which develop
KEY POINTS
GTKO donor organs eliminate the role of anti-Gal antibody in xenograft rejection.
Cytotoxic non-Gal antibody is commonly present in nonhuman primates. Preformed non-Gal antibody contributes to early cardiac xenograft injury and is sufficient to induce hyperacute rejection at low frequency.
Survival of GTKO and GTKO;hCRP organs has improved, but organ rejection remains an antibodymediated process with chronic vascular antibody deposition and variable complement activation.
Orthotopic cardiac xenotransplantation is limited by early perioperative cardiac xenograft dysfunction (PCXD), not observable in heterotopic xenotransplantation. The origin of PCXD may be related to porcine cardiac ischemic injury and the effects of preformed non-Gal antibody.
Further progress toward clinical use of cardiac xenotransplantation will require techniques to mitigate PCXD and new therapies to control both preformed and induced non-Gal antibody.
in response to intestinal microflora [20] . Naive human and nonhuman primate sera include antibody reactivity to GTKO pig cells. This non-Gal antibody reactivity is mainly composed of IgM in nonhuman primates and in humans is a mixture of IgG and IgM. Preformed non-Gal antibody is cytotoxic to GTKO peripheral blood mononuclear cells in most human sera and about 64% of baboon sera [21, 22] . The level of non-Gal antibody and cytotoxicity is generally reduced compared with wildtype pig cells and there is a wide range of individual variation.
The impact of preformed non-Gal antibody in CXTx is not evident using recipients with minimal antibody reactivity to GTKO pig cells. Recent studies using recipients with demonstrable preformed non-Gal antibody report early immune injury to GTKO hearts, including an instance of hyperacute rejection [23,24,25 & ]. GTKO cardiac xenograft survival of less than 1 day was observed in the absence of immunosuppression and early graft failure was reported in recipients with variant subtherapeutic levels of immunosuppression [24,25 & ]. Rejection was characterized by vascular antibody and complement (C4d) deposition, microvascular thrombosis, and graft infiltration by neutrophils and macrophages. We reported hyperacute rejection of a GTKO cardiac xenograft in a recipient treated with a full regimen of immunosuppression [23] . At explant, 90 min after reperfusion, the histology showed extensive intramyocardial hemorrhage, vascular IgM, and C5b deposition ( Fig. 2a-c ). Despite elimination of aGal antigen, these studies show that preformed non-Gal antibody is commonly present and can induce early graft injury. This finding suggests that methods to deplete or block preformed non-Gal antibodies may be needed to prevent early graft injury and GTKO xenograft rejection.
Human preformed non-Gal antibody includes antibody reactivity to terminally linked N-glycolylneuraminic acid (anti-Neu5Gc) [26] . The Neu5Gc sialic acid modification is produced by hydroxylation of N-acetylneuraminic acid (Neu5Ac) through CMP-Neu5Ac hydroxylase (CMAH) [27] . A mutation of the CMAH locus eliminates this pathway in humans, but not nonhuman primates. Anti-Neu5Gc antibody is estimated to constitute 7-13% of the preformed non-Gal human antibody repertoire [28] . The potential for anti-Neu5Gc antibody to affect cardiac xenograft rejection remains unclear as they are not present in nonhuman primates, and binding of anti-Neu5Gc may be highly context-dependent [27] . The development of a targeted CMAH mutation in mice, which eliminates expression of the Neu5Gc antigen will be useful to define the potential role of anti-Neu5Gc antibody to mediated organ rejection [29] .
Several studies have attempted to identify non-Gal antigenic targets detected after CXTx. Yeh et al. [30] used sensitized baboon sera to screen a panel of 15 prospective glycan polyacrylamide conjugates. These neoconjugates included blood group A and B glycans, aGal, a-lactoasamine and b-lactoasamine, Forssman disaccharide, sulphated derivatives of b-lactosamine, Neu5Gc, Neu5Ac, P1, Pk, and Lewis A, B, and C glycans. GTKO-sensitized baboon sera showed no specific induced immune response to any of these glycans. In contrast, Diswall et al. [11] detected an induced antibody response to an undefined acidic glycolipid present in GTKO tissue. We have examined the specificity and diversity of induced non-Gal IgG using proteomic and expression library screening methods [23,31 && ]. These studies identified both protein and putative carbohydrate non-Gal antigens ( Table 1) . Expression library screening identified a porcine glycosyl transferase homologous to human and murine b1-4 N-acetylgalactosaminyl transferase 2 (B4GALNT2) [32, 33] . Lectin and antibody binding suggests that human cells expressing the porcine B4GALNT2 homologue produce a CADlike glycan [32] , which may be consistent with the acidic glycolipid response reported by Diswall et al. [11] .
Our analysis suggests that the induced non-Gal antibody response is directed to a limited number of non-Gal antigens composed of members of the heat shock and annexin protein families, porcine complement, and thromboregulatory proteins. Induced antibody responses to porcine fibronectin, the endothelial cell protein C receptor, CD46 and the B4GALNT2 produced glycan are frequently observed [23,31 && ]. Antibody responses to these non-Gal antigens may contribute to xenograft rejection by blocking key endothelial cell functions which directly or indirectly contribute to microvascular thrombosis. This may occur if non-Gal antibody blocks the function of annexin A2 (ANAX2) which regulates fibrin deposition [34] , porcine CD46 and CD59, which control complement amplification, porcine GRP78, and ECPCR involved in regulating thrombosis and inflammation [35, 36] and CD9 involved in platelet activation [37] . If this is the case, then substitution of the human gene for these non-Gal targets could eliminate the induced antibody response and maintain key endothelial cell functions to promote graft survival. Likewise, elimination of the glycan produced by the porcine B4GALNT2 homologue could further reduce the antigenicity of pig organs.
ORTHOTOPIC CARDIAC XENOTRANSPLANTATION
Pig-to-primate CXTx has mainly been studied using the abdominal heterotopic transplantation model. This is an immunological model as the xenograft is perfused and beating but does not contribute to circulation. Median heterotopic cardiac xenograft survival of 3 months has been achieved [5] with individual survival beyond 8 months [25 & ].
Replicating these results with life-supporting orthotopic transplantation might justify future clinical applications [38] . The number of reported orthotopic pig-to-primate cardiac transplants is limited [39] [40] [41] [42] [43] [44] [45] 46 && ] with survival ranging from 1 to 57 days. In this difficult model, recipient death was mainly from postoperative complications with several cases explanted between 9 and 57 days showing little histologic evidence of DXR. This finding suggests that the efficacy of life-sustaining CXTx is limited by postoperative complications and not cardiac function.
These studies also identify a problem in orthotopic CXTx, which was not apparent in heterotopic CXTx. Each research group reported variable perioperative mortality ranging from 40 to 60% within the first 48 h (Fig. 3) . Xenograft failure was not due to hyperacute rejection as the explanted hearts showed vascular antibody deposition but otherwise mainly normal myocardial histology (Fig. 2d-f ). Early graft failure was mainly due to primary organ dysfunction. This primary organ dysfunction that we have called perioperative cardiac xenograft dysfunction (PCXD) is a significant barrier to the clinical application of CXTx. PCXD may occur due to xenotransplantationspecific factors, such as the use of young donor organs, the inflammatory effects of preformed non-Gal antibody, and incompatibility between porcine and primate plasma, including known dysfunctions in thromboregulation and may be further effected by pig-specific factors, most notably the sensitivity of the pig heart to cardiopulmonary bypass and ischemia-reperfusion (I/R) injury [47, 48] . If this is the case, then a combination of pretransplant immunoabsorption, cardiac preconditioning [49] , or pharmacological treatments to improve cardiac resistance to I/R injury [50, 51] may modulate PCXD. Genetic modification to increase adenosine receptor [52] and CD39 expression [53] in the heart or to increase the number of collateral arteries [54] might also alleviate PCXD. It is important to note that PCXD is not an insurmountable barrier as 20-50% of current orthotopic xenografts recover from the initial effect. Over a period of 1-2 weeks, these hearts recover full cardiac function and can go on to support the life of the primate for nearly 2 months [43] .
Recently, there was the first report of pig-tobaboon heterotopic intrathoracic cardiac xenotransplantation (HTCXTx) [55 & ]. The HTCXTx model is a load-bearing heterotopic transplant in which both the donor and recipient heart contribute to circulation. Reichart et al. [55 & ] demonstrated the feasibility of this complex surgical procedure and show good GTKO;CD46 porcine cardiac function for 45 days using clinical immunosuppression. As circulation of the recipient is not fully dependent on xenograft function, the HTCXTx model may be an important model to study PCXD and to define diagnostic criteria and methods to treat and reverse DXR. HTCXTx may also be an alternative clinical application.
GENE EXPRESSION DURING ORTHOTOPIC CARDIAC XENOTRANSPLANTATION
We recently reported a genome-wide scan of changes in porcine cardiac gene expression after orthotopic CXTx [56 && ]. In cardiac xenografts subject to PCXD, DXR, or recovered from recipients who died of transplant complications in the absence of strong histologic evidence of rejection (surviving grafts), we identified a set of 260 genes with widely variant changes in gene expression compared to control not transplanted pig hearts. This analysis showed that all orthotopic samples, including those from hearts not subject to DXR, showed evidence of inflammation and myocardial injury consistent with the effects of cytokines and antibody-mediated inflammation. There was also evidence of altered gene expression indicative of a cardioprotective response. As surviving hearts were fully supporting the circulation of the recipient and not rejected by DXR despite vascular antibody deposition, this analysis suggests that for long periods of time, there is a dynamic endothelial cell response which balances hemostasis against the prothrombotic effects of endothelial cell activation. DXR with microvascular thrombosis and coagulative necrosis may be induced when this balance is pushed toward thrombosis. This event might occur after an induced antibody response, when key endothelial cell functions are blocked, or as a result of species-specific dysfunctions in coagulation.
COAGULATION AND XENOGRAFT REJECTION
Fibrin and platelet-rich microvascular thrombosis and myocardial coagulative necrosis are the prominent histologic features of GTKO cardiac xenograft rejection. Similar pathology is seen only in severe manifestations of antibody-mediated allograft rejection [57] . It is unclear whether this difference is the consequence of higher concentrations and greater diversity of non-Gal antibody, or due to known disparities in hemostatic regulation between pigs and humans [58] . Dysfunction of porcine thrombomodulin, and von Willebrand factor, spontaneous porcine endothelial cell-dependent aggregation of human platelets, and loss of CD39 expression from activated endothelial cells would all promote intragraft thrombosis [59] [60] [61] [62] . These disparities may also contribute to systemic derangement of coagulation parameters sometimes reported after xenotransplantation [63] . Systemic therapies using clinical antiplatelet and antithrombotic drugs or using activated protein C fail to prevent microvascular thrombosis, fibrin deposition, or prolong xenograft survival [64] [65] [66] [67] [68] . This result may be due to the level of redundancy in hemostatic regulation, the intensity of non-Gal antibody-mediated rejection, or a failure to durably control hemostasis at the surface of the vascular endothelial cells. Numerous transgenic donor pigs designed to effect coagulation have recently been reported [69] [70] [71] [72] [73] [74] [75] , but their ability to prevent microvascular thrombosis, systemic coagulopathies, or prolong graft survival remains to be tested.
CONCLUSION
GTKO organs have eliminated the role of anti-Gal in DXR, but DXR remains an aggressive form of antibody-mediated rejection involving chronic non-Gal antibody-induced endothelial cell activation and injury and possible species-restricted dysfunctions in hemostasis. New methods to block the effects of preformed and induced non-Gal antibody may be required for durable xenograft survival. Orthotopic CXTx has demonstrated the ability of the porcine heart to support life in the nonhuman primate model for up to 2 months; however, the efficacy of this approach is limited by early xenograft dysfunction. If improvements in early cardiac xenograft function can be achieved, then CXTx has the potential to make a significant impact in future cardiovascular care.
